We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Cyprotex | LSE:CRX | London | Ordinary Share | GB00BP25RZ14 | ORD £0.01 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 160.50 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
LONDON--Cyprotex PLC (CRX.LN), the preclinical ADME-Tox services company, Tuesday announced a collaborative research agreement between its wholly owned subsidiary Apredica LLC and Pfizer Inc. (PFE).
MAIN FACTS:
-No financial details have been disclosed
-The deal extends over an eighteen month period and is split into two stages with the second stage being dependent on certain milestones being achieved
-The collaboration is a research-based project which the parties aim to evaluate, further develop, and improve several of Cyprotex's proprietary offerings in the area of predictive toxicology
-Shares closed Monday at 4.25 pence valuing the company at GBP10 million.
Write to Jana Weigand at jana.weigand@dowjones.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Cyprotex Chart |
1 Month Cyprotex Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
